Welcome to our dedicated page for GE HealthCare Technologies news (Ticker: GEHC), a resource for investors and traders seeking the latest updates and insights on GE HealthCare Technologies stock.
GE HealthCare Technologies Inc. develops medical technology, pharmaceutical diagnostics, and AI, cloud and software solutions for healthcare providers. News about GEHC commonly covers its Advanced Imaging Solutions, Pharmaceutical Diagnostics, and Patient Care Solutions businesses, including MR, CT, molecular imaging, women’s health, X-ray, ultrasound, image-guided solutions, and enterprise imaging.
Company updates also address quarterly results, orders and backlog, operational changes, acquisitions such as Intelerad, and product or collaboration announcements. Recurring themes include next-generation SIGNA MR systems, helium-free MR technology, bkActiv intraoperative ultrasound integration, AI-powered mammography tools, and the mangaciclanol MRI contrast-agent pipeline.
GE HealthCare (Nasdaq: GEHC) reorganized operations and executive leadership effective April 29, 2026 to streamline execution, accelerate innovation, and drive growth. The company created Advanced Imaging Solutions (AIS) — a combined Imaging and Advanced Visualization Solutions segment sized at $14.6 billion — led by Phil Rackliffe.
Catherine Estrampes becomes Chief Commercial and Growth Officer to lead a new Global Markets region (all markets except China). Roland Rott will leave the company. GE HealthCare will recast financials to reflect the new segment structure in its Q2 2026 SEC filings.
GE HealthCare (Nasdaq: GEHC) said members of its management team will present at two investor conferences in May and June 2026. Bank of America Health Care Conference presentation is May 12, 2026 at 10:40 am PT / 1:40 pm ET. Jefferies Global Healthcare Conference presentation is June 3, 2026 at 9:20 am ET. Webcasts will be available on the company investor website on the listed dates.
GE HealthCare (Nasdaq: GEHC) announced the first patient was dosed in the international Phase 2/3 LUMINA trial of its manganese-based MRI contrast agent, mangaciclanol, on April 23, 2026.
Mangaciclanol has FDA Fast Track designation for adults and pediatric patients aged 2+, showed tolerability in Phase 1, and demonstrates comparable relaxivity to gadobutrol. The company highlights potential supply and environmental advantages versus gadolinium agents. Mangaciclanol remains investigational and is not approved for clinical use.
GE HealthCare (Nasdaq: GEHC) expanded its collaboration with DeepHealth (RadNet subsidiary) to commercially extend DeepHealth’s AI-powered Breast Suite internationally and integrate new applications with GE’s Pristina Via mammography systems. The deal adds ProFound Pro, Safeguard Review, and cloud-first workflow tools to scale AI-enabled breast cancer screening and second‑reader workflows.
GE HealthCare (NYSE:GEHC) announced a commercial digital integration linking the bkActiv intraoperative ultrasound system with the Medtronic Stealth AXiS surgical navigation system to provide real-time imaging during cranial procedures.
The integration supports plug-and-play visualization to help assess anatomy changes such as brain shift and complements planning, navigation and robotics; the Stealth AXiS has U.S. FDA clearance for cranial procedures.
GE HealthCare (Nasdaq: GEHC) will release first quarter 2026 financial results before market open on Wednesday, April 29, 2026.
The GE HealthCare management team will host a live conference call and webcast at 8:30 a.m. ET the same day. Materials and a replay will be posted on the company investor website.
GE HealthCare (Nasdaq: GEHC) warns shareholders to reject an unsolicited mini-tender by Potemkin Limited offering up to 100,000 shares at $45.80 per share. The offer price is ~34.80% below the $70.25 closing price on March 18, 2026.
The company says the offer contains conditions, potential payment delays, and limited withdrawal rights, urges investors to obtain current market quotations, consult advisors, and take no action if they have not tendered.
GE HealthCare (Nasdaq: GEHC) will serve as the industry lead in COMPASS, a five-year, EU-funded IHI consortium with a total budget of €50.5 million and more than 60 partners to advance early detection and prediction of cardiotoxicity in cancer patients across Europe. The grant agreement was signed on March 25, 2026.
COMPASS will combine AI, advanced imaging, biomarkers and integrated care pathways to develop predictive tools, multi-omics biomarkers and an AI-powered clinical decision support pathway aimed at earlier diagnosis and coordinated cardio-oncology care.
GE HealthCare (Nasdaq: GEHC) will showcase cardiology innovations at ACC.26, including the newly U.S. FDA 510(k) cleared Photonova Spectra photon‑counting CT, ReadyFix fleet management for MAC VU360 ECG workstations, a U.S. collaboration with Gentuity, and recent Allia Moveo regulatory clearances.
Highlights emphasize ultra‑high‑definition imaging, AI‑enabled workflows, intravascular visualization, and operational tools intended to improve diagnostic confidence and device uptime across the cardiac care pathway.
GE HealthCare (Nasdaq: GEHC) received U.S. FDA 510(k) clearance for Photonova Spectra, a photon-counting CT system featuring Deep Silicon detectors with 8-bin energy resolution, 0.23s rotation speed, NVIDIA-accelerated reconstruction and a one-scan universal workflow. GE expects its innovation investments to support 1–2% revenue growth.